Cargando…
Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients
AIMS/INTRODUCTION: The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944841/ https://www.ncbi.nlm.nih.gov/pubmed/31240874 http://dx.doi.org/10.1111/jdi.13108 |
_version_ | 1783485084564717568 |
---|---|
author | Ishibashi, Chisaki Kozawa, Junji Hosakawa, Yoshiya Yoneda, Sho Kimura, Takekazu Fujita, Yukari Fukui, Kenji Iwahashi, Hiromi Shimomura, Iichiro |
author_facet | Ishibashi, Chisaki Kozawa, Junji Hosakawa, Yoshiya Yoneda, Sho Kimura, Takekazu Fujita, Yukari Fukui, Kenji Iwahashi, Hiromi Shimomura, Iichiro |
author_sort | Ishibashi, Chisaki |
collection | PubMed |
description | AIMS/INTRODUCTION: The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type of fat to glucose metabolism in type 2 diabetes patients by cross‐sectional and longitudinal analyses. MATERIAL AND METHODS: A total of 56 patients with type 2 diabetes who had been hospitalized twice were analyzed. We evaluated the mean computed tomography values of the pancreas (P), liver (L) and spleen (S). Lower computed tomography values indicate a greater fat content. We defined indices of pancreatic or liver fat content as the differences between P or L and S. We assessed the associations among fat content for the two organs (P‐S, L‐S) and clinical parameters at the first hospitalization, and then analyzed the associations between these fat contents and changes in glycometabolic markers (the second data values minus the first). RESULTS: In the cross‐sectional study, P‐S negatively correlated with the increment of C‐peptide in the glucagon stimulation test (r = −0.71, P < 0.0001) and body mass index (r = −0.28, P = 0.034). L‐S negatively correlated with homeostasis model assessment of insulin resistance (r = −0.73, P < 0.0001), body mass index (r = −0.62, P < 0.0001) and some other obesity‐related indicators, but not with the increment of C‐peptide in the glucagon stimulation test. In the longitudinal study, P‐S positively correlated with the change of the increment of C‐peptide in the glucagon stimulation test (r = 0.49, P = 0.021). CONCLUSIONS: In type 2 diabetes patients, pancreatic fat was less associated with obesity‐related indicators than liver fat, but was more strongly associated with the longitudinal decrease in endogenous insulin‐secreting capacity. |
format | Online Article Text |
id | pubmed-6944841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69448412020-01-09 Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients Ishibashi, Chisaki Kozawa, Junji Hosakawa, Yoshiya Yoneda, Sho Kimura, Takekazu Fujita, Yukari Fukui, Kenji Iwahashi, Hiromi Shimomura, Iichiro J Diabetes Investig Articles AIMS/INTRODUCTION: The relationship between pancreatic fatty infiltration and diabetes is widely known, whereas the causal relationship is not clear. Furthermore, it is uncertain whether pathogenesis of pancreatic fat is similar to that of liver fat. We aimed to clarify the contribution of this type of fat to glucose metabolism in type 2 diabetes patients by cross‐sectional and longitudinal analyses. MATERIAL AND METHODS: A total of 56 patients with type 2 diabetes who had been hospitalized twice were analyzed. We evaluated the mean computed tomography values of the pancreas (P), liver (L) and spleen (S). Lower computed tomography values indicate a greater fat content. We defined indices of pancreatic or liver fat content as the differences between P or L and S. We assessed the associations among fat content for the two organs (P‐S, L‐S) and clinical parameters at the first hospitalization, and then analyzed the associations between these fat contents and changes in glycometabolic markers (the second data values minus the first). RESULTS: In the cross‐sectional study, P‐S negatively correlated with the increment of C‐peptide in the glucagon stimulation test (r = −0.71, P < 0.0001) and body mass index (r = −0.28, P = 0.034). L‐S negatively correlated with homeostasis model assessment of insulin resistance (r = −0.73, P < 0.0001), body mass index (r = −0.62, P < 0.0001) and some other obesity‐related indicators, but not with the increment of C‐peptide in the glucagon stimulation test. In the longitudinal study, P‐S positively correlated with the change of the increment of C‐peptide in the glucagon stimulation test (r = 0.49, P = 0.021). CONCLUSIONS: In type 2 diabetes patients, pancreatic fat was less associated with obesity‐related indicators than liver fat, but was more strongly associated with the longitudinal decrease in endogenous insulin‐secreting capacity. John Wiley and Sons Inc. 2019-07-27 2020-01 /pmc/articles/PMC6944841/ /pubmed/31240874 http://dx.doi.org/10.1111/jdi.13108 Text en © 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Ishibashi, Chisaki Kozawa, Junji Hosakawa, Yoshiya Yoneda, Sho Kimura, Takekazu Fujita, Yukari Fukui, Kenji Iwahashi, Hiromi Shimomura, Iichiro Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients |
title | Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients |
title_full | Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients |
title_fullStr | Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients |
title_full_unstemmed | Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients |
title_short | Pancreatic fat is related to the longitudinal decrease in the increment of C‐peptide in glucagon stimulation test in type 2 diabetes patients |
title_sort | pancreatic fat is related to the longitudinal decrease in the increment of c‐peptide in glucagon stimulation test in type 2 diabetes patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944841/ https://www.ncbi.nlm.nih.gov/pubmed/31240874 http://dx.doi.org/10.1111/jdi.13108 |
work_keys_str_mv | AT ishibashichisaki pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT kozawajunji pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT hosakawayoshiya pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT yonedasho pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT kimuratakekazu pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT fujitayukari pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT fukuikenji pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT iwahashihiromi pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients AT shimomuraiichiro pancreaticfatisrelatedtothelongitudinaldecreaseintheincrementofcpeptideinglucagonstimulationtestintype2diabetespatients |